Loading…
Antitumor Activities of a Novel 9‐Aminoanthracycline (SM‐5887) against Mouse Experimental Tumors and Human Tumor Xenografts
The antitumor effects of SM‐5887, a totally synthetic 9‐aminoanthracycline derivative, were evaluated in six murinc experimental tumor systems (P38S, Ehrlich carcinoma, sarcoma 180, Lewis lung carcinoma, B16 melanoma and colon 38) and nine human tumor‐nude mouse systems (one breast cancer, two lung...
Saved in:
| Published in: | Cancer science 1989-01, Vol.80 (1), p.69-76 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c5679-726a0f9cfac0e9d569debaa0896304c6a8bab242076f014ffa12bd70db74fd083 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c5679-726a0f9cfac0e9d569debaa0896304c6a8bab242076f014ffa12bd70db74fd083 |
| container_end_page | 76 |
| container_issue | 1 |
| container_start_page | 69 |
| container_title | Cancer science |
| container_volume | 80 |
| creator | Morisada, Shinya Yanagi, Yoshikazu Noguchi, Toshihiro Kashiwazaki, Yasuo Fukui, Masaru |
| description | The antitumor effects of SM‐5887, a totally synthetic 9‐aminoanthracycline derivative, were evaluated in six murinc experimental tumor systems (P38S, Ehrlich carcinoma, sarcoma 180, Lewis lung carcinoma, B16 melanoma and colon 38) and nine human tumor‐nude mouse systems (one breast cancer, two lung cancers and six gastric cancers). Characteristically SM‐5887 showed excellent antitumor activities, superior to adriamycin (ADR), against human tumor xenografts, although its activities against murine experimental tumors were almost equal to those of ADR. When the human tumors were implanted sc in female athymic mice (BALB/c, nu/nu) and their volume reached 100‐ 300 mm3, SM‐5887 and ADR were injected iv. All nine human tumors tested showed statistically significant responses to SM‐5887, and 7 of them were strongly suppressed in their growth by SM‐5887 so that minimum T/C values were less than 30% at the maximum tolerated dose (MTD, 25 mg/kg) with a single iv injection. Compared with ADR, SM‐5887 was statistically more effective in five tumors (one breast, one lung and three gastric), equal in two tumors (two gastric), and less potent in two tumors (one lung and one gastric). In addition, the 10‐day‐interval repeated iv treatments with SM‐5887 at the MTD (25 mg/kg) resulted in remarkably potent antitumor effects (including complete regression) against human gastric cancer, 4‐1ST, implanted in nude mice without enhancement of toxic effects, SM‐5887 was also effective against ip‐inoculated P388 by oral administration as well as iv injection. |
| doi_str_mv | 10.1111/j.1349-7006.1989.tb02247.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5917680</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2399081184</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5679-726a0f9cfac0e9d569debaa0896304c6a8bab242076f014ffa12bd70db74fd083</originalsourceid><addsrcrecordid>eNqVkc2O0zAUhSMEGjoDj4BkAYth0XKdHyceCaSoKgzSDCwYJHbWjWN3XKV2sZPSruAReEaeBFeNKljijSWfc8891pckzynMaDyvVzOa5XxaArAZ5RWf9Q2kaV7Odg-SyUl6mEyAU5gWUMDj5DyEFQAtgaVnyVmacwaMTpIfte1NP6ydJ7Xszdb0RgXiNEHy0W1VR_jvn7_qtbEObX_vUe5lZ6wil59vo1BUVfmK4BKNDT25dUNQZLHbKG_WyvbYkbtDciBoW3I9rNEeH8hXZd3So-7Dk-SRxi6op-N9kXx5t7ibX09vPr3_MK9vprJgZfxPyhA0lxolKN4WjLeqQYSKswxyybBqsEnzFEqmgeZaI02btoS2KXPdQpVdJG-PuZuhWatWxnoeO7GJTdHvhUMj_lWsuRdLtxUFpyWrIAa8GAO8-zao0IuVG7yNnUWacQ4VpVUeXVdHl_QuBK_0aQMFcWAnVuIASBwAiQM7MbITuzj87O-Op9ERVtRfjjoGiZ32aKUJJxuLbHleRtubo-276dT-PwqIeb1gPPsDK6K6CA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2399081184</pqid></control><display><type>article</type><title>Antitumor Activities of a Novel 9‐Aminoanthracycline (SM‐5887) against Mouse Experimental Tumors and Human Tumor Xenografts</title><source>PubMed Central Free</source><source>Publicly Available Content Database</source><creator>Morisada, Shinya ; Yanagi, Yoshikazu ; Noguchi, Toshihiro ; Kashiwazaki, Yasuo ; Fukui, Masaru</creator><creatorcontrib>Morisada, Shinya ; Yanagi, Yoshikazu ; Noguchi, Toshihiro ; Kashiwazaki, Yasuo ; Fukui, Masaru</creatorcontrib><description>The antitumor effects of SM‐5887, a totally synthetic 9‐aminoanthracycline derivative, were evaluated in six murinc experimental tumor systems (P38S, Ehrlich carcinoma, sarcoma 180, Lewis lung carcinoma, B16 melanoma and colon 38) and nine human tumor‐nude mouse systems (one breast cancer, two lung cancers and six gastric cancers). Characteristically SM‐5887 showed excellent antitumor activities, superior to adriamycin (ADR), against human tumor xenografts, although its activities against murine experimental tumors were almost equal to those of ADR. When the human tumors were implanted sc in female athymic mice (BALB/c, nu/nu) and their volume reached 100‐ 300 mm3, SM‐5887 and ADR were injected iv. All nine human tumors tested showed statistically significant responses to SM‐5887, and 7 of them were strongly suppressed in their growth by SM‐5887 so that minimum T/C values were less than 30% at the maximum tolerated dose (MTD, 25 mg/kg) with a single iv injection. Compared with ADR, SM‐5887 was statistically more effective in five tumors (one breast, one lung and three gastric), equal in two tumors (two gastric), and less potent in two tumors (one lung and one gastric). In addition, the 10‐day‐interval repeated iv treatments with SM‐5887 at the MTD (25 mg/kg) resulted in remarkably potent antitumor effects (including complete regression) against human gastric cancer, 4‐1ST, implanted in nude mice without enhancement of toxic effects, SM‐5887 was also effective against ip‐inoculated P388 by oral administration as well as iv injection.</description><identifier>ISSN: 0910-5050</identifier><identifier>ISSN: 1347-9032</identifier><identifier>EISSN: 1349-7006</identifier><identifier>EISSN: 1876-4673</identifier><identifier>DOI: 10.1111/j.1349-7006.1989.tb02247.x</identifier><identifier>PMID: 2496061</identifier><identifier>CODEN: GANNA2</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Administration, Oral ; Animals ; Anthracycline ; Anthracyclines ; Antibiotics, Antineoplastic - therapeutic use ; Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; Antitumor activity ; Biological and medical sciences ; Breast cancer ; Chemotherapy ; Colon ; Doxorubicin - therapeutic use ; Gastric cancer ; Humans ; Injection ; Lung cancer ; Lung carcinoma ; Male ; Medical sciences ; Melanoma ; Mice ; Mice, Inbred Strains ; Neoplasm Transplantation ; Neoplasms, Experimental - drug therapy ; Oral administration ; Pharmacology. Drug treatments ; Sarcoma ; SM‐5887 ; Statistical analysis ; Transplantation, Heterologous ; Tumors ; Xenografts</subject><ispartof>Cancer science, 1989-01, Vol.80 (1), p.69-76</ispartof><rights>1990 INIST-CNRS</rights><rights>Copyright John Wiley & Sons, Inc. Jan 1989</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5679-726a0f9cfac0e9d569debaa0896304c6a8bab242076f014ffa12bd70db74fd083</citedby><cites>FETCH-LOGICAL-c5679-726a0f9cfac0e9d569debaa0896304c6a8bab242076f014ffa12bd70db74fd083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2399081184/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2399081184?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,25753,27923,27924,27925,37012,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=6706947$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2496061$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morisada, Shinya</creatorcontrib><creatorcontrib>Yanagi, Yoshikazu</creatorcontrib><creatorcontrib>Noguchi, Toshihiro</creatorcontrib><creatorcontrib>Kashiwazaki, Yasuo</creatorcontrib><creatorcontrib>Fukui, Masaru</creatorcontrib><title>Antitumor Activities of a Novel 9‐Aminoanthracycline (SM‐5887) against Mouse Experimental Tumors and Human Tumor Xenografts</title><title>Cancer science</title><addtitle>Jpn J Cancer Res</addtitle><description>The antitumor effects of SM‐5887, a totally synthetic 9‐aminoanthracycline derivative, were evaluated in six murinc experimental tumor systems (P38S, Ehrlich carcinoma, sarcoma 180, Lewis lung carcinoma, B16 melanoma and colon 38) and nine human tumor‐nude mouse systems (one breast cancer, two lung cancers and six gastric cancers). Characteristically SM‐5887 showed excellent antitumor activities, superior to adriamycin (ADR), against human tumor xenografts, although its activities against murine experimental tumors were almost equal to those of ADR. When the human tumors were implanted sc in female athymic mice (BALB/c, nu/nu) and their volume reached 100‐ 300 mm3, SM‐5887 and ADR were injected iv. All nine human tumors tested showed statistically significant responses to SM‐5887, and 7 of them were strongly suppressed in their growth by SM‐5887 so that minimum T/C values were less than 30% at the maximum tolerated dose (MTD, 25 mg/kg) with a single iv injection. Compared with ADR, SM‐5887 was statistically more effective in five tumors (one breast, one lung and three gastric), equal in two tumors (two gastric), and less potent in two tumors (one lung and one gastric). In addition, the 10‐day‐interval repeated iv treatments with SM‐5887 at the MTD (25 mg/kg) resulted in remarkably potent antitumor effects (including complete regression) against human gastric cancer, 4‐1ST, implanted in nude mice without enhancement of toxic effects, SM‐5887 was also effective against ip‐inoculated P388 by oral administration as well as iv injection.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Anthracycline</subject><subject>Anthracyclines</subject><subject>Antibiotics, Antineoplastic - therapeutic use</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antitumor activity</subject><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>Chemotherapy</subject><subject>Colon</subject><subject>Doxorubicin - therapeutic use</subject><subject>Gastric cancer</subject><subject>Humans</subject><subject>Injection</subject><subject>Lung cancer</subject><subject>Lung carcinoma</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Melanoma</subject><subject>Mice</subject><subject>Mice, Inbred Strains</subject><subject>Neoplasm Transplantation</subject><subject>Neoplasms, Experimental - drug therapy</subject><subject>Oral administration</subject><subject>Pharmacology. Drug treatments</subject><subject>Sarcoma</subject><subject>SM‐5887</subject><subject>Statistical analysis</subject><subject>Transplantation, Heterologous</subject><subject>Tumors</subject><subject>Xenografts</subject><issn>0910-5050</issn><issn>1347-9032</issn><issn>1349-7006</issn><issn>1876-4673</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqVkc2O0zAUhSMEGjoDj4BkAYth0XKdHyceCaSoKgzSDCwYJHbWjWN3XKV2sZPSruAReEaeBFeNKljijSWfc8891pckzynMaDyvVzOa5XxaArAZ5RWf9Q2kaV7Odg-SyUl6mEyAU5gWUMDj5DyEFQAtgaVnyVmacwaMTpIfte1NP6ydJ7Xszdb0RgXiNEHy0W1VR_jvn7_qtbEObX_vUe5lZ6wil59vo1BUVfmK4BKNDT25dUNQZLHbKG_WyvbYkbtDciBoW3I9rNEeH8hXZd3So-7Dk-SRxi6op-N9kXx5t7ibX09vPr3_MK9vprJgZfxPyhA0lxolKN4WjLeqQYSKswxyybBqsEnzFEqmgeZaI02btoS2KXPdQpVdJG-PuZuhWatWxnoeO7GJTdHvhUMj_lWsuRdLtxUFpyWrIAa8GAO8-zao0IuVG7yNnUWacQ4VpVUeXVdHl_QuBK_0aQMFcWAnVuIASBwAiQM7MbITuzj87O-Op9ERVtRfjjoGiZ32aKUJJxuLbHleRtubo-276dT-PwqIeb1gPPsDK6K6CA</recordid><startdate>198901</startdate><enddate>198901</enddate><creator>Morisada, Shinya</creator><creator>Yanagi, Yoshikazu</creator><creator>Noguchi, Toshihiro</creator><creator>Kashiwazaki, Yasuo</creator><creator>Fukui, Masaru</creator><general>Blackwell Publishing Ltd</general><general>Japanese Cancer Association</general><general>John Wiley & Sons, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>198901</creationdate><title>Antitumor Activities of a Novel 9‐Aminoanthracycline (SM‐5887) against Mouse Experimental Tumors and Human Tumor Xenografts</title><author>Morisada, Shinya ; Yanagi, Yoshikazu ; Noguchi, Toshihiro ; Kashiwazaki, Yasuo ; Fukui, Masaru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5679-726a0f9cfac0e9d569debaa0896304c6a8bab242076f014ffa12bd70db74fd083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Anthracycline</topic><topic>Anthracyclines</topic><topic>Antibiotics, Antineoplastic - therapeutic use</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antitumor activity</topic><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>Chemotherapy</topic><topic>Colon</topic><topic>Doxorubicin - therapeutic use</topic><topic>Gastric cancer</topic><topic>Humans</topic><topic>Injection</topic><topic>Lung cancer</topic><topic>Lung carcinoma</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Melanoma</topic><topic>Mice</topic><topic>Mice, Inbred Strains</topic><topic>Neoplasm Transplantation</topic><topic>Neoplasms, Experimental - drug therapy</topic><topic>Oral administration</topic><topic>Pharmacology. Drug treatments</topic><topic>Sarcoma</topic><topic>SM‐5887</topic><topic>Statistical analysis</topic><topic>Transplantation, Heterologous</topic><topic>Tumors</topic><topic>Xenografts</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morisada, Shinya</creatorcontrib><creatorcontrib>Yanagi, Yoshikazu</creatorcontrib><creatorcontrib>Noguchi, Toshihiro</creatorcontrib><creatorcontrib>Kashiwazaki, Yasuo</creatorcontrib><creatorcontrib>Fukui, Masaru</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morisada, Shinya</au><au>Yanagi, Yoshikazu</au><au>Noguchi, Toshihiro</au><au>Kashiwazaki, Yasuo</au><au>Fukui, Masaru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antitumor Activities of a Novel 9‐Aminoanthracycline (SM‐5887) against Mouse Experimental Tumors and Human Tumor Xenografts</atitle><jtitle>Cancer science</jtitle><addtitle>Jpn J Cancer Res</addtitle><date>1989-01</date><risdate>1989</risdate><volume>80</volume><issue>1</issue><spage>69</spage><epage>76</epage><pages>69-76</pages><issn>0910-5050</issn><issn>1347-9032</issn><eissn>1349-7006</eissn><eissn>1876-4673</eissn><coden>GANNA2</coden><abstract>The antitumor effects of SM‐5887, a totally synthetic 9‐aminoanthracycline derivative, were evaluated in six murinc experimental tumor systems (P38S, Ehrlich carcinoma, sarcoma 180, Lewis lung carcinoma, B16 melanoma and colon 38) and nine human tumor‐nude mouse systems (one breast cancer, two lung cancers and six gastric cancers). Characteristically SM‐5887 showed excellent antitumor activities, superior to adriamycin (ADR), against human tumor xenografts, although its activities against murine experimental tumors were almost equal to those of ADR. When the human tumors were implanted sc in female athymic mice (BALB/c, nu/nu) and their volume reached 100‐ 300 mm3, SM‐5887 and ADR were injected iv. All nine human tumors tested showed statistically significant responses to SM‐5887, and 7 of them were strongly suppressed in their growth by SM‐5887 so that minimum T/C values were less than 30% at the maximum tolerated dose (MTD, 25 mg/kg) with a single iv injection. Compared with ADR, SM‐5887 was statistically more effective in five tumors (one breast, one lung and three gastric), equal in two tumors (two gastric), and less potent in two tumors (one lung and one gastric). In addition, the 10‐day‐interval repeated iv treatments with SM‐5887 at the MTD (25 mg/kg) resulted in remarkably potent antitumor effects (including complete regression) against human gastric cancer, 4‐1ST, implanted in nude mice without enhancement of toxic effects, SM‐5887 was also effective against ip‐inoculated P388 by oral administration as well as iv injection.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>2496061</pmid><doi>10.1111/j.1349-7006.1989.tb02247.x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0910-5050 |
| ispartof | Cancer science, 1989-01, Vol.80 (1), p.69-76 |
| issn | 0910-5050 1347-9032 1349-7006 1876-4673 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5917680 |
| source | PubMed Central Free; Publicly Available Content Database |
| subjects | Administration, Oral Animals Anthracycline Anthracyclines Antibiotics, Antineoplastic - therapeutic use Antineoplastic agents Antineoplastic Agents - therapeutic use Antitumor activity Biological and medical sciences Breast cancer Chemotherapy Colon Doxorubicin - therapeutic use Gastric cancer Humans Injection Lung cancer Lung carcinoma Male Medical sciences Melanoma Mice Mice, Inbred Strains Neoplasm Transplantation Neoplasms, Experimental - drug therapy Oral administration Pharmacology. Drug treatments Sarcoma SM‐5887 Statistical analysis Transplantation, Heterologous Tumors Xenografts |
| title | Antitumor Activities of a Novel 9‐Aminoanthracycline (SM‐5887) against Mouse Experimental Tumors and Human Tumor Xenografts |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T03%3A21%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antitumor%20Activities%20of%20a%20Novel%209%E2%80%90Aminoanthracycline%20(SM%E2%80%905887)%20against%20Mouse%20Experimental%20Tumors%20and%20Human%20Tumor%20Xenografts&rft.jtitle=Cancer%20science&rft.au=Morisada,%20Shinya&rft.date=1989-01&rft.volume=80&rft.issue=1&rft.spage=69&rft.epage=76&rft.pages=69-76&rft.issn=0910-5050&rft.eissn=1349-7006&rft.coden=GANNA2&rft_id=info:doi/10.1111/j.1349-7006.1989.tb02247.x&rft_dat=%3Cproquest_pubme%3E2399081184%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5679-726a0f9cfac0e9d569debaa0896304c6a8bab242076f014ffa12bd70db74fd083%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2399081184&rft_id=info:pmid/2496061&rfr_iscdi=true |